Apellis Pharmaceuticals Inc (NAS:APLS)
$ 39.68 -3.92 (-8.99%) Market Cap: 4.82 Bil Enterprise Value: 5.07 Bil PE Ratio: 0 PB Ratio: 18.04 GF Score: 38/100

Apellis Pharmaceuticals Inc at Evercore ISI HealthCONx Conference Transcript

Nov 28, 2023 / 03:00PM GMT
Release Date Price: $47.16 (-2.34%)
Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

Okay. Excellent. Well, listen, Tim, why don't you kick it off? We'll jump right in. I think we have Jazz coming up in about 15 minutes, but jump right in.

Timothy E. Sullivan
Apellis Pharmaceuticals, Inc. - CFO & Treasurer

Sure. Sure.

Questions & Answers

Umer Raffat
Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research

So let's start with the latest update. Where are we right now in commercial launch and in the debates of the day?

Timothy E. Sullivan
Apellis Pharmaceuticals, Inc. - CFO & Treasurer

Sure. So in the third quarter, we announced that we had $75 million in revenue of SYFOVRE, we had $24 million in revenue with EMPAVELI. So the launch is underway. And as you probably all saw or most of you saw from our third quarter earnings, we had a nice rebound in our revenue and our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot